SRT-2104 MONOHYDRATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H24N6O2S2.H2O
Molecular Weight	534.653
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4

InChI

InChIKey=PPHQATZJSPAXLZ-UHFFFAOYSA-N

InChI=1S/C26H24N6O2S2.H2O/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31;/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33);1H2

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C26H24N6O2S2
Molecular Weight	516.638
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20601277
Curator's Comment: description was created based on several sources, including

SRT2104, also known as GSK2245840, is a novel, first in class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias. SRT2104 in the phase II of clinical trial to treat type 2 diabetes mellitus and psoriasis also in the phase I for its use in case of colitis. Also was reported, that we report that SRT2104, penetrated the blood-brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntington's disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
NAD-dependent deacetylase sirtuin 1 19 Target ID: CHEMBL4506 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20601277	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Psoriasis 87 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26556603	Primary	Phase II 1147	Unknown Approved Use Unknown
Type 2 diabetes mellitus 262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27239324	Primary	Phase II 1147	Unknown Approved Use Unknown
Ulcerative colitis 125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26595549	Primary	Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
536.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	2 g 1 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
452.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	1 g 1 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
293.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.5 g 1 times / day multiple, oral dose: 0.5 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
218.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.25 g 1 times / day multiple, oral dose: 0.25 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
127.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.1 g 1 times / day multiple, oral dose: 0.1 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
50.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.03 g 1 times / day multiple, oral dose: 0.03 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1874 ng/mL REVIEW https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142081.s003&type=supplementary	2 g 1 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FED
261.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	3 g 1 times / day multiple, oral dose: 3 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
3665 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	2 g 1 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3087 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	1 g 1 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1878 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.5 g 1 times / day multiple, oral dose: 0.5 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1191 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.25 g 1 times / day multiple, oral dose: 0.25 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
602 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.1 g 1 times / day multiple, oral dose: 0.1 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
247 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.03 g 1 times / day multiple, oral dose: 0.03 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13997 ng × h/mL REVIEW https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142081.s003&type=supplementary	2 g 1 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FED
1573 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	3 g 1 times / day multiple, oral dose: 3 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
14.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	2 g 1 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	1 g 1 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.5 g 1 times / day multiple, oral dose: 0.5 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.25 g 1 times / day multiple, oral dose: 0.25 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.1 g 1 times / day multiple, oral dose: 0.1 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	0.03 g 1 times / day multiple, oral dose: 0.03 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23.7 h REVIEW https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142081.s003&type=supplementary	100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN
25.5 h REVIEW https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142081.s003&type=supplementary	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN
14.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22616762	3 g 1 times / day multiple, oral dose: 3 g route of administration: Oral experiment type: MULTIPLE co-administered:	SRT-2104 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34292	https://www.001chemical.com/chem/search?q=DY34292
1PlusChem LLC	1P008U06	https://www.1pchem.com/search?query=1P008U06
AChemBlock	M15341	http://www.achemblock.com/catalogsearch/result/?q=M15341
AK Scientific	4043AH	https://aksci.com/item_detail.php?cat=4043AH
ApexBio Technology	A3821	https://www.apexbt.com/catalogsearch/result/?q=A3821
AstaTech	41745	http://astatechinc.com/CPSResult.php?CRNO=41745
BLD Pharm	BD629892	http://www.bldpharm.com/search/Search.html?keyword=BD629892
BOC Sciences	1093403-33-8	http://www.bocsci.com/description.asp?cas=1093403-33-8
Chem Scene	CS-0955	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0955
ChemShuttle	152087	https://www.chemshuttle.com/catalogsearch/result/?q=152087
eMolecules	44811452	https://orderbb.emolecules.com/search/#?query=44811452
eNovation Chemicals	D566574	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D566574&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A1287	http://www.excenen.com/searchresultlist.php?id=EX-A1287
KeyOrganics	AS-57311	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-57311
mcule	MCULE-4627502253	https://mcule.com/MCULE-4627502253/
MedChem Express	HY-15262	https://www.medchemexpress.com/search.html?q=HY-15262&ft=&fa=&fp=
Molcore	MC34292	http://www.molcore.com/CatMC34292.html
Molnova	M17806	https://www.molnova.com/en/serch-list.html?keywords=M17806
MolPort	MolPort-035-944-346	https://www.molport.com/shop/molecule-link/MolPort-035-944-346
MuseChem	I000394	https://www.musechem.com/product/I000394.html
Selleck Chemicals	S7792	http://www.selleckchem.com/search.html?searchDTO.searchParam=S7792
ShangHai Biochempartner	BCP17468	http://www.biochempartner.com/search_BCP17468
TargetMol	T6679	https://www.targetmol.com/search?keyword=T6679

PubMed

Title	Date	PubMed
The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans.	2015-06	25978169
Sirtuin 1 activator SRT2104 protects Huntington's disease mice.	2014-12	25574479
SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass.	2014-10	24931715

Patents

Sample Use Guides

In Vivo Use Guide

oral administration (10–300 mg/kg/day; for five to 28 days)

Route of Administration: Oral

In Vitro Use Guide

C2C12 cells were treated with vehicle (0.1% DMSO) or 3 μM SRT2104 for 24 h. RelA/p65 protein levels were upregulated in C2C12 myoblasts in response to SRT2104 treatment. SRT2104 led to lower acetylation of RelA/p65 in C2C12 myoblasts, likely due to selective activation of SIRT1

Substance Class	Chemical Created by `admin` on `Wed Apr 02 19:43:40 GMT 2025` Edited by `admin` on `Wed Apr 02 19:43:40 GMT 2025`
Record UNII	TAY7MHA9NH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SRT2104 MONOHYDRATE

Preferred Name

English

SRT-2104 MONOHYDRATE

Common Name

English

5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)-, monohydrate

Systematic Name

English

Code System Code Type Description

FDA UNII

TAY7MHA9NH

Created by admin on Wed Apr 02 19:43:40 GMT 2025 , Edited by admin on Wed Apr 02 19:43:40 GMT 2025

PRIMARY

Related Record Type Details


					4521NR0J09

SRT-2104

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					4521NR0J09

SRT-2104

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20601277Curator's Comment: description was created based on several sources, including

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Cmax

AUC

T1/2

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20601277
Curator's Comment: description was created based on several sources, including

C_max

T_1/2